Atossa Genetics -15% on heels of critical FDA report


Atossa Genetics (ATOS -15.3%) slides sharply after the Food and Drug Administration issues a consumer update on nipple aspirators used for breast cancer screening, saying a mammogram is still the best way to detect breast cancer.

The update slammed ATOS' claim that its ForeCYTE Breast Health Test was "literally a Pap smear for breast cancer"; the nipple aspiration test has no such evidence supporting it, the FDA says.

In October, ATOS recalled the breast cancer test from the market.

Comments (5)
  • dacama1
    , contributor
    Comments (221) | Send Message
     
    How does a company think they can get away with actions like this?
    13 Dec 2013, 10:32 AM Reply Like
  • PSalerno
    , contributor
    Comments (4694) | Send Message
     
    It is not the first time. Companies try to develop products, but it is not an easy task.
    13 Dec 2013, 10:37 AM Reply Like
  • pat walsh
    , contributor
    Comments (337) | Send Message
     
    Women need all the help in fighting breast cancer.by the time you get a mammogram it could be to late.
    13 Dec 2013, 12:18 PM Reply Like
  • rolfriebe
    , contributor
    Comments (3) | Send Message
     
    the interpretation on what ATOS is claiming and what ATOS is saying is not clear at all. It need to be refraced.Thanks.

     

    Der Gewinner
    13 Dec 2013, 01:41 PM Reply Like
  • rolfriebe
    , contributor
    Comments (3) | Send Message
     
    A proper explaination is needed on what Atos is claiming and What Atos is saying. Thanks

     

    Der Gewinner
    13 Dec 2013, 01:41 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs